Case Study:
Faster Time to Reimbursement
How to Use AI for Faster Time to Reimbursement
According to Pharmaceutic Executive, a delay in launch can cost a company an average of $15 million per drug, per day. This project was about using Artificial Intelligence to speed up the time to reimbursement on different formularies after FDA approval.
The Client Problem
Thee client analysed how many $ were left on the table with every day delay to reimbursement approval in different formularies. They wanted to see if Artificial Intelligence could impact this positively and speed up time to reimbursement thereby increasing revenue from their products.
The Solution
Using a combination of different AI techniques, to:
- identify the factors affecting time-to-reimbursement for newly launched medicines post market approval,
- provide insight into what to include in, or leave out of submissions for formulary inclusion
- find other important considerations and insights that have worked in the past to accelerate time-to-reimbursement.
The Outcome
Reimbursement was achieved much faster in the pilot of formularies using AI versus the ones not using AI. The average improvement in speed was 6 weeks. At an average of $15 m/day that can be left on the table, the amount of revenue gained from this simple increase in speed to reimbursement allowed a significant return on investment and the approach is now being rolled out to other products as well.
To achieve these kinds of results, contact Eularis today.
Latest Blogs
Check out our latest blogs

PharmacoVigilence 4.0: Transforming Data into Decisions with AI
PharmacoVigilence (PV) is therefore a critical step in the development and commercialisation of pharmaceutical drugs, and absolutely essential in terms of patient safety. Over time,

AI and Diversity & Inclusion: Building Equitable Technology for All
Quietly, every day, in boardrooms across Silicon Valley to Singapore, a new wave of artificial intelligence systems are making thousands of decisions that shape our lives

How Pharma Companies Can Build Trustworthy AI Agents
In an industry where a single miscalculation can impact millions of lives, pharmaceutical companies are witnessing an unprecedented transformation through AI agents – autonomous systems